3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA
Shareholder votes, Reg. FD
Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Investor Presentation
.2
Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload
Delisting Amendment
Free Writing Prospectus